{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:21:53Z","timestamp":1791570113167,"version":"4.3.4"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T00:00:00Z","timestamp":1323043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0025096","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T16:55:03Z","timestamp":1323104103000},"page":"e25096","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":86,"title":["Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA\/SCID Mice"],"prefix":"10.1371","volume":"6","author":[{"given":"Nicolas","family":"Brezillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Massinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Giang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Berissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Belghiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hannoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherard","family":"Puerstinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Soussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serban","family":"Morosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Kremsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,12,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2008.12.003","article-title":"Hepatitis B virus induced hepatocellular carcinoma.","volume":"286","author":"I Chemin","year":"2009","journal-title":"Cancer Lett"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease.","volume":"49","author":"TJ Liang","year":"2009","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B.","volume":"49","author":"R Perrillo","year":"2009","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1002\/hep.22920","article-title":"Benefits and risks of nucleoside analog therapy for hepatitis B.","volume":"49","author":"JL Dienstag","year":"2009","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","article-title":"Hepatitis B: reflections on the current approach to antiviral therapy.","volume":"48","author":"F Zoulim","year":"2008","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.","volume":"76","author":"JJ Feld","year":"2007","journal-title":"Antiviral Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1128\/JVI.76.10.4848-4854.2002","article-title":"A small molecule inhibits and misdirects assembly of hepatitis B virus capsids.","volume":"76","author":"A Zlotnick","year":"2002","journal-title":"J Virol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"11933","DOI":"10.1128\/JVI.77.22.11933-11940.2003","article-title":"The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture.","volume":"77","author":"X Lu","year":"2003","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","article-title":"Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.","volume":"54","author":"O Weber","year":"2002","journal-title":"Antiviral Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus.","volume":"84","author":"C Xu","year":"2010","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.","volume":"299","author":"K Deres","year":"2003","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.bcp.2003.08.001","article-title":"Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion.","volume":"66","author":"HJ Hacker","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly.","volume":"102","author":"SJ Stray","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nbt1187","article-title":"An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly.","volume":"24","author":"SJ Stray","year":"2006","journal-title":"Nat Biotechnol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41\u20134109 has multiple effects on Hepatitis B virus capsid assembly.","volume":"19","author":"SJ Stray","year":"2006","journal-title":"J Mol Recognit"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.toxlet.2007.07.010","article-title":"NMR-spectroscopy-based metabonomic approach to the analysis of Bay41\u20134109, a novel anti-HBV compound, induced hepatotoxicity in rats.","volume":"173","author":"C Shi","year":"2007","journal-title":"Toxicol Lett"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/jhep.2001.23314","article-title":"Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus.","volume":"33","author":"M Dandri","year":"2001","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","article-title":"Near completely humanized liver in mice shows human-type metabolic responses to drugs.","volume":"165","author":"C Tateno","year":"2004","journal-title":"Am J Pathol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhep.2004.09.021","article-title":"Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.","volume":"42","author":"M Dandri","year":"2005","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.20657","article-title":"Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.","volume":"41","author":"P Meuleman","year":"2005","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3727\/096368908786516800","article-title":"Rescue of fertility in homozygous mice for the urokinase plasminogen activator transgene by the transplantation of mouse hepatocytes.","volume":"17","author":"N Brezillon","year":"2008","journal-title":"Cell Transplantation"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/500840","article-title":"Liver-stage development of Plasmodium falciparum, in a humanized mouse model.","volume":"193","author":"S Morosan","year":"2006","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","article-title":"Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepetitis B virus DNA.","volume":"84","author":"MA Sells","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1099\/vir.0.004861-0","article-title":"Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells.","volume":"90","author":"O Hantz","year":"2009","journal-title":"J Gen Virol"},{"key":"ref25","article-title":"Dihydropyrimidines and their use in the treatment of hepatitis B.","author":"J Stolting","year":"2000"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/589623","article-title":"Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease.","volume":"198","author":"P Soussan","year":"2008","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.antiviral.2008.07.006","article-title":"The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.","volume":"80","author":"P Meuleman","year":"2008","journal-title":"Antiviral Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1128\/JVI.80.6.2797-2807.2006","article-title":"Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus.","volume":"80","author":"P Meuleman","year":"2006","journal-title":"J Virol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0025096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T15:53:21Z","timestamp":1588953201000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0025096"}},"subtitle":[],"editor":[{"given":"Matthew L.","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,5]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0025096","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.724168572.793514555","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,5]]}}}